The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer
Abstract
Purpose: Black women with breast cancer are known to have poorer survival than white women. Suboptimal treatment may compromise the survival benefits of adjuvant chemotherapy. We analyzed the association of race and survival with duration of treatment and number of treatment cycles among women receiving chemotherapy for early-stage breast cancer. Patients and Methods: Patients were women in the Henry Ford Health System tumor registry who were diagnosed with stage I/II breast cancer between January 1, 1996, and December 31, 2001, who received adjuvant chemotherapy. We calculated an observed/expected ratio of treatment duration and of completed chemotherapy cycles for each patient. Using Cox proportional hazards models, we analyzed the association of early treatment termination and treatment duration with all-cause mortality, controlling for age, race, stage, hormone receptor status, grade, comorbidity score, and doxorubicin use. Results: Of 472 eligible patients, 28% (31% black, 23% white; P = .03) received fewer cycles of treatment than expected. Black race, receipt of ≤ 75% of the expected number of cycles, increasing age, hormone receptor negativity, and a comorbidity score of more than 1 were associated with poorer survival. Among the 344 patients receiving the expected number of cycles, 60% experienced delays. These delays did not reduce survival. Conclusion: This study is the first to find that a substantial fraction of women with early-stage breast cancer terminated their chemotherapy prematurely and that early termination was associated with both black race and poorer survival. A better understanding of the determinants of suboptimal treatment may lead to interventions that can reduce racial disparities and improve breast cancer outcomes for all women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321401 · Cited by 1,049
Racial Differences in the Treatment of Early-Stage Lung Cancer
Bach, P. B., Cramer, L. D., Warren, J. L., & Begg, C. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411606 · Cited by 994
Primary Care Physicians Who Treat Blacks and Whites
Bach, P. B., Pham, H. H., Schrag, D., Tate, R. C., & Hargraves, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmsa040609 · Cited by 986
Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer
Bonadonna, G., & Valagussa, P. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101013040103 · Cited by 774
Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer
Budman, D. R., Berry, D. A., Cirrincione, C. T., Henderson, Wood, W. C., Weiss, R. B., Ferree, C. R., Muss, H. B., Green, M. R., Norton, L., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1205 · Cited by 577
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301801 · Cited by 577
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310226 · Cited by 556
Clegg, L. X., Li, F. P., Hankey, B. F., Chu, K., & Edwards, B. K. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.17.1985 · Cited by 535
Influence of Hospital Procedure Volume on Outcomes Following Surgery for Colon Cancer
Schrag, D. (2000) · JAMA · doi:10.1001/jama.284.23.3028 · Cited by 490
Cited by
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
Self-citationHershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.-Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 828
Self-citationMorris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., Schwartz, G. F., Park, P. K., Rosenberg, A. L., Brill, K., et al. (2007) · Cancer · doi:10.1002/cncr.22836 · Cited by 602
Annual report to the nation on the status of cancer, part 1: National cancer statistics
Cronin, K. A., Scott, S., Firth, A. U., Sung, H., Henley, S. J., Sherman, R. L., Siegel, R. L., Anderson, R. N., Kohler, B. A., Benard, V. B., et al. (2022) · Cancer · doi:10.1002/cncr.34479 · Cited by 557
Booth, C. M., & Tannock, I. F. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.725 · Cited by 469
Hershman, D. L., McBride, R. B., Eisenberger, A., Tsai, W. Y., Grann, V. R., & Jacobson, J. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1242 · Cited by 390
Self-citationChemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5841 · Cited by 335
Self-citationSilber, J. H., Rosenbaum, P. R., Clark, A. S., Giantonio, B. J., Ross, R. N., Teng, Y., Wang, M., Niknam, B. A., Ludwig, J. M., Wang, W., et al. (2013) · JAMA · doi:10.1001/jama.2013.8272 · Cited by 305
Cancer, Culture, and Health Disparities: Time to Chart a New Course?
Kagawa-Singer, M., Valdez Dadia, A., Yu, M. C., & Surbone, A. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20051 · Cited by 280
Aminkeng, F., Bhavsar, A. P., Visscher, H., Rassekh, S. R., Li, Y., Lee, J. W., Brunham, L. R., Caron, H. N., van Dalen, E. C., Kremer, L. C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3374 · Cited by 278
Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
O'Donnell, P. H., & Dolan, M. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0344 · Cited by 261
Racial and ethnic disparities in hematologic malignancies
Kirtane, K., & Lee, S. J. (2017) · Blood · doi:10.1182/blood-2017-04-778225 · Cited by 168
Ell, K., Vourlekis, B., Xie, B., Nedjat‐Haiem, F. R., Lee, P., Muderspach, L., Russell, C., & Palinkas, L. A. (2009) · Cancer · doi:10.1002/cncr.24500 · Cited by 132
Livaudais, J. C., Hershman, D. L., Habel, L., Kushi, L., Gomez, S. L., Li, C. I., Neugut, A. I., Fehrenbacher, L., Thompson, B., & Coronado, G. D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1762-1 · Cited by 93
“Differences in the use of other types of breast cancer treatment not captured by population-based cancer registries, including adjuvant chemotherapy and adjuvant hormonal therapy, may contribute to remaining survival differences [3–5].”
BackgroundSelf-citationNeugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L., Leoce, N., Nathanson, S. D., Ambrosone, C. B., Bovbjerg, D. H., Mandelblatt, J. S., Magai, C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2066-9 · Cited by 63
Self-citationAdam, H., Yang, M. Y., Cato, K., Baldini, I., Senteio, C., Celi, L. A., Zeng, J., Singh, M., & Ghassemi, M. (2022) · Proceedings of the 2022 AAAI/ACM Conference on AI, Ethics, and Society · doi:10.1145/3514094.3534203 · Cited by 33
Metadata
- Authors
- Hershman, D., McBride, R., Jacobson, J. S., Lamerato, L., Roberts, K., Grann, V. R., & Neugut, A. I.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-09-20
- Volume
- 23
- Issue
- 27
- Pages
- 6639-6646
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166647521
- Cited by
- 308
- References
- 35
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.